In vivo, MYTX‐011 exhibited enhanced antitumor efficacy across several NSCLC xenograft models, including those with epidermal growth factor receptor (EGFR) and kirsten rat sarcoma virus (KRAS) mutations, and those that expressed c‐MET at various levels. Here, EGFR is linked to non-small cell lung carcinoma.